<DOC>
	<DOCNO>NCT00322595</DOCNO>
	<brief_summary>The primary purpose study evaluate efficacy ( SEROQUEL SRâ„¢ ) quetiapine fumarate sustained-release ( SR ) compare placebo treatment anxiety symptom patient generalized anxiety disorder ( GAD ) . PLEASE NOTE : Seroquel SR Seroquel XR refer formulation . The SR designation change XR consultation FDA .</brief_summary>
	<brief_title>Efficacy Safety Study Seroquel SR Treatment Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Male female age 18 65 year ; A diagnosis generalize anxiety disorder ; Absence current episode major depression . The presence history schizophrenia psychotic disorder ; Hypertension ; A current diagnosis cancer , unless remission least 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Anxiety</keyword>
	<keyword>GAD</keyword>
</DOC>